NEWS IN BRIEF Eusa Pharma focuses on biopharma with two strategic moves 25-Jul-2018 By Ben Hargreaves Eusa Pharma has completed the acquisition of global rights for J&J’s Sylvant, shortly after selling its critical care business to Serb Pharmaceuticals.